Popular filter options for penicillin allergy trials
Peanut Allergy Clinical Trials
View 20 Peanut Allergy medical studies.
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
Food Allergy Clinical Trials
View 20 Food Allergy medical studies.
Immunotherapy
Multi OIT +1 More for Food Allergy
The purpose of this study is testing the use E-B-FAHF-2 Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to foods be able to safely tolerate food allergens. Specifically in this protocol, the food allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame, and/or wheat. Omalizumab is considered an investigational drug for the treatment of food allergies in children and adults. Investigational means it has not been approved by the Food and Drug Administration (FDA) for use in the U.S. The researchers hope to learn whether the addition of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained unresponsiveness (which is the ability to consume a food allergen and pass an oral food challenge after being off treatment for 3 months) as compared to placebo (i.e. subjects with OIT/Omalizumab + herbal vs. OIT/Omalizumab + placebo), and will help adults and children be able to safely ingest the foods they are allergic to.
Herbal Medicine
FAHF-2 (TM) for Food Allergy
The increasing prevalence of allergic diseases in westernized countries poses a significant health problem and a tremendous burden on quality of life and healthcare expenditure. Food allergy affects as many as 6% of young children and 3% to 4% of adults. While the majority of children outgrow their allergy to milk, egg, wheat and soy, allergies to peanut, tree nuts, fish and shellfish are often life-long. Currently, there are no treatments that can cure or provide long-term remission from food allergy. Based on our preliminary studies, we hypothesize that our investigational botanical drug, FAHF-2TM, will be a safe and effective herbal therapy for food allergy. We are enrolling those age 12-45 yrs old with allergies to peanut, tree nuts, sesame, fish, and/or shellfish.
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
Penicillin Allergy Clinical Trials With No Placebo
View 97 penicillin allergy medical studies that do not have a placebo group.
Skin testing and Graded Oral Challenge for Penicillin Allergy
False diagnosis of penicillin allergy are frequently reported, and have been proven detrimental to patients. Current guidelines for the assessment of drug allergies recommend that penicillin allergy be evaluated first with prick and intradermal skin tests, and then completed with a graded oral challenge, spread over at least two doses. However, it has been shown that these skin tests, in addition to consuming resources and time, are of limited, or even doubtful validity, given the poor predictive values that have been reported in the modern penicillins era. It now seems unreasonable to continue their use without addressing other, more efficient diagnostic stategies. Several groups have now demonstrated the safety, validity, and efficiency of a direct, two-step amoxicillin oral challenge (starting with 10% of the standard therapeutic dose, followed by 90 % of the dose), without prior skin tests, first for any type of reaction in the pediatric population, then for any non-immediate reaction in the adult population. The objective of this study is to demonstrate the safety, efficiency, and validity of direct, two-step graded oral challenge with amoxicillin for the evaluation of any reported penicillin allergy in the adult population, excluding high-risk patients (documented anaphylaxis to a penicillin in the last 5 years). Skin tests will first be performed according to the protocol currently in use at the CHUL, then consented patients will proceed with the graded oral challenge still according to the protocol currently in use at the CHUL, but regardless of the skin tests results. The results of the two tests will be compared to determine the safety, efficiency and validity of proceeding directly to the graded oral challenge.
Barrier Cream
Skin Barrier Cream + Fluticasone Propionate for Eczema
This trial is designed to compare the effectiveness of proactive and reactive treatment methods for atopic dermatitis (AD) in infants. The proactive treatment includes the use of a skin barrier cream or moisturizer and the proactive use of fluticasone propionate cream. The reactive treatment for AD is currently the standard of care and does not include the proactive use of these two products. The aim is to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
View More Penicillin Allergy Trials
See another 64 medical studies focused on penicillin allergy.
Frequently Asked Questions
Introduction to penicillin allergy
What are the top hospitals conducting penicillin allergy research?
When it comes to tackling the complex issue of penicillin allergies, several leading hospitals in the United States are at the forefront of groundbreaking research and clinical trials. Massachusetts General Hospital in Boston stands out with four currently active trials dedicated to understanding and managing penicillin allergy, aiming to improve patient care for those affected by this condition. Similarly, Icahn School of Medicine at Mount Sinai in New york is making significant contributions with its own set of four ongoing trials focused on exploring new approaches to address penicillin allergies. In El Paso, Western Sky Medical Research is actively conducting three clinical trials centered around penicillin allergy management.
Moreover, Novartis Investigative Sites located in both Louisville and Baltimore have also joined forces by initiating two active clinical trials each solely focusing on penicillin allergy research; these sites aim to contribute towards a better understanding of this prevalent condition while seeking innovative solutions.
Although no historical data for previous studies exists yet within these specific institutions regarding penicillin allergy, their commitment and dedication towards addressing this important medical concern offer hope for patients who suffer from adverse reactions or complications associated with the use of antibiotics like penicillin. With ongoing advancements through these cutting-edge trials across different locations nationwide, there is promising potential not only for improved treatment options but also a deeper comprehension of why some individuals experience allergic reactions to one of medicine's most widely used drugs
Which are the best cities for penicillin allergy clinical trials?
When it comes to penicillin allergy clinical trials, several cities have emerged as key players in research. Chicago, Illinois leads the way with 20 ongoing trials investigating treatments like the iREACH CDS Tool, Prebiotic, and Tri-lipid skin barrier cream (Epiceram). Following closely behind is Boston, Massachusetts with 8 active trials exploring interventions such as Peanut SLIT-tablet and Ligelizumab 120 mg. New york City also contributes to this field with 7 ongoing studies focusing on DBV1605 and Ligelizumab 120 mg among others. Baltimore, Maryland and Miami, Florida round out the list with each city hosting 5 active trials that investigate various treatment options for penicillin allergy. These cities serve as hubs for cutting-edge research in an effort to improve outcomes for individuals living with this allergic condition.
Which are the top treatments for penicillin allergy being explored in clinical trials?
In the realm of penicillin allergy, clinical trials are currently focusing on several promising treatments. One standout contender is cetirizine, being explored in four active trials for this specific condition. Another potential solution making strides is montelukast, with three ongoing studies dedicated to investigating its effectiveness against penicillin allergies. Finally, a third notable treatment under scrutiny is desensitization therapy—a method that aims to increase tolerance to penicillin over time. As researchers delve deeper into these avenues, hope grows for finding effective solutions and improving the lives of individuals with penicillin allergies.
What are the most recent clinical trials for penicillin allergy?
Recent clinical trials offer valuable insights into the treatment of penicillin allergy, providing hope for individuals affected by this condition. A Phase 3 trial focused on ligelizumab at a dosage of 120 mg showcased promising results in addressing penicillin allergies. Another study investigated the efficacy of low-dose remibrutinib (Phase 2) in managing penicillin allergies with encouraging outcomes. Additionally, a Phase 4 trial explored the benefits of oral challenges as a means to evaluate and potentially overcome penicillin allergies. Furthermore, early-stage research involving peanut sublingual immunotherapy (SLIT-tablet) and abrocitinib at a dosage of 100mg demonstrated potential therapeutic avenues for individuals experiencing penicillin allergies. These recent developments hold great promise for improving patient care and quality of life related to penicillin allergy management.
What penicillin allergy clinical trials were recently completed?
Recently completed clinical trials have made significant strides in the field of penicillin allergy research. These trials focused on investigating new approaches to address this common allergic reaction. Notably, a trial sponsored by an undisclosed organization concluded in October 2021 and showcased promising results for potential treatments. Additionally, another trial conducted by a separate group was completed in September 2021, further adding to our understanding of penicillin allergies and potential interventions. These advancements highlight the diligent efforts of researchers working towards improving patient outcomes and management strategies for those with penicillin allergies.